Clinical trials: Low Dose
Peptic Ulcer [Iowa Type (107680.0010)]
Risk of Uncomplicated Peptic Ulcer in the General Population
The analyses are conducted in a previous population-based cohort study using The Health Improvement Network database in the UK (Cai et al 2009).The aims of the post hoc analyses are: To estimate the relative risk of uncomplicated…
- Trial name
- NCT01888588
- Testing
- Risk of symptomatic peptic ulcer
- Where
- Spain
- Volunteers
- 4,000 people
- Sponsor
- AstraZeneca
Healthy Participants, Dyslipidemia
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4954 in Healthy Adult Participants With or Without Elevated Lipoprotein (a) (Lp[a]) Levels, and Participants With Dyslipidemia
The purpose of the study is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple ascending doses of AZD4954 in healthy participants with or without elevated Lipoprotein(a)…
- Trial name
- NCT06980428
- Testing
- AZD4954
- Where
- 6 sites in United States
- Volunteers
- 171 people
- Sponsor
- AstraZeneca
HIV Infections
The Safety and Effectiveness of Three Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Taken AZT
To evaluate the safety and efficacy of low and high doses of lamivudine ( 3TC ) in combination with zidovudine ( AZT ) and zalcitabine ( dideoxycytidine; ddC ) in combination with AZT.
- Trial name
- NCT00002436
- Testing
- Lamivudine, Zidovudine, Zalcitabine
- Where
- 22 sites in United States, Canada and 1 more
- Volunteers
- 325 people
- Sponsor
- Glaxo Wellcome
Hepatitis C, Chronic
A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection
This randomized, open-label, active-controlled, parallel-group study will evaluate the sustained virological response of danoprevir boosted with low dose ritonavir in combination with Pegasys (peginterferon alfa-2a) and Copegus…
- Trial name
- NCT01220947
- Testing
- Copegus, Danoprevir, Pegasys
- Where
- 68 sites in United States, Austria and 9 more
- Volunteers
- 421 people
- Sponsor
- Hoffmann-La Roche
Healthy
Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of a New Ultra Low Molecular Weight Heparin (RO-14) Administered Subcutaneously Increasing Single-doses to Healthy Male Volunteers
Clinical trial to evaluate the tolerability and pharmacokinetics of a new ultra low molecular weight heparin (RO-14) administered subcutaneously increasing single-doses to healthy male volunteers
- Trial name
- NCT00629733
- Testing
- RO-14
- Where
- Spain
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Rovi Pharmaceuticals Laboratories
Motion Sickness
Pharmacokinetic and Efficacy Profile Intranasal Scopolamine Spray
Part 1, the pharmacokinetic (PK) phase, will expand upon the pilot study conducted at Naval Medical Research Laboratory (NAMRL) and has the goal of determining bioavailability and time to Cmax in a larger representative sample.
- Trial name
- NCT02155309
- Testing
- Scopolamine
- Where
- United States
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Repurposed Therapeutics, Inc.
Hypophosphatasia (HPP)
Safety Study of Human Recombinant Tissue Non-Specific Alkaline Phosphatase Fusion Protein Asfotase Alfa in Adults With Hypophosphatasia (HPP)
This clinical trial studies the safety, tolerability, and pharmacology of asfotase alfa when given to adults with HPP.
- Trial name
- NCT00739505
- Testing
- Asfotase Alfa
- Where
- 3 sites in United States, Canada
- Volunteers
- 6 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Inclisiran Formulation
Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a New Formulation of Inclisiran Containing Polysorbate 80 Compared to the Currently Marketed Formulation
The purpose of this study is to compare safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of the currently marketed formulation of inclisiran with a new formulation containing polysorbate 80 (PS80), after a…
- Trial name
- NCT07626281
- Testing
- Inclisiran formulation containing PS80, Currently marketed inclisiran formulation
- Where
- 6 sites in United States
- Volunteers
- 152 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Contraception
Study of Safety and Efficacy of an Oral Contraceptive
This is a non-comparative study. The primary objective of the study is to assess the efficacy of a low dose oral contraceptive in the prevention of pregnancy.
- Trial name
- NCT00391807
- Testing
- Norethindrone acetate/ethinyl estradiol
- Where
- 66 sites in United States
- Volunteers
- 1,683 people, healthy volunteers welcome
- Sponsor
- Warner Chilcott
Smoking, Non-smoking
Smoking Research Study
The purpose of this study is to develop a fit-for-purpose biochemical verification tool that can be used to detect concomitant use of a few (less than 5) conventional cigarettes.
- Trial name
- NCT01465880
- Testing
- Part A
- Where
- United Kingdom
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Philip Morris Products S.A.
Stomach Ulcer, Duodenal Ulcer
MK0782 + Low-Dose Aspirin 7-Day Erosion Endoscopy Study (0782-001)
This study will determine how if MK0782 is safe and tolerable and to determine how often and the severity of stomach and small intestine ulcers develop following administration of MK0782 plus enteric coated aspirin, rofecoxib…
- Trial name
- NCT00543868
- Testing
- MK0782
- Volunteers
- 462 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
HIV Infections
TMC114-C227: A Study to Evaluate the Effectiveness and Safety of TMC114 (Darunavir) With a Low Dose of Ritonavir as Monotherapy (no Other Anti-HIV Drugs Will be Given) in Patients Who Have Never Been Treated With Antiretrovirals (Anti-HIV Drugs) Previously
This is an open label study (no placebos are used; all patients will receive the true medication) to evaluate the effectiveness of TMC114/rtv in treatment naÃ-ve (never previously received anti-HIV drugs), HIV 1 infected patients.
- Trial name
- NCT00513513
- Testing
- TMC114 (darunavir) / ritonavir
- Volunteers
- 7 people
- Sponsor
- Tibotec Pharmaceuticals, Ireland
OSTEOPOROSIS, POSTMENOPAUSAL
Risedronate in Postmenopausal Women With Low Bone Density
The primary objective of this pilot study is to estimate the percent change from baseline at Week 4, Month 6 in NTX bone turnover marker for a monthly 150mg dose of risedronate administered for 6 months and a loading dose regimen…
- Trial name
- NCT00351091
- Testing
- RISEDRONATE
- Volunteers
- 150 people
- Sponsor
- Sanofi
Cervical Intraepithelial Neoplasia
Dose-finding Study of Hexaminolevulinate (HAL) Photodynamic Therapy (PDT) to Treat Cervical Neoplasia
An effective and safe medical therapy would be most welcome to reduce the need for surgical interventions and related adverse events and psychological impact on patients with cervical cancer precursors.
- Trial name
- NCT01256424
- Testing
- HAL 5% with illumination, HAL 1% with illumination, HAL 0.2% with illumination
- Where
- 2 sites in Germany, Norway
- Volunteers
- 262 people
- Sponsor
- Photocure
Hepatitis C Virus (HCV)
Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Low-Dose Ribavirin QD in Subjects With Genotype 1a Chronic Hepatitis C Virus Infection
This study seeks to assess the safety and efficacy of treatment with ombitasvir/paritaprevir/ritonavir and dasabuvir with low-dose ribavirin in non-cirrhotic, genotype 1a (GT1a) hepatitis C virus infected participants who are…
- Trial name
- GEODE II (NCT02609659)
- Testing
- ombitasvir/paritaprevir/ritonavir and dasabuvir, ribavirin
- Volunteers
- 105 people
- Sponsor
- AbbVie
Acute Myeloid Leukemia
Study to Investigate the Efficacy, Safety and Tolerability of AZD1152 Alone and in Combination With Low Dose Cytosine Arabinoside (LDAC)in Acute Myeloid Leukaemia (AML) Patients
The purpose of this study is to assess the efficacy, safety and tolerability of AZD1152 alone and in combination with low dose cytosine arabinoside (LDAC) in comparison with LDAC alone in AML patients.
- Trial name
- SPARK-AML1 (NCT00952588)
- Testing
- AZD1152, LDAC
- Where
- 45 sites in United States, Australia and 7 more
- Volunteers
- 74 people
- Sponsor
- AstraZeneca
Low Back Pain
A Study on Efficacy (Effectiveness), Safety, and Impact on Quality of Life Measures of Dilaudid CR (Controlled Release);, Hydromorphone HCl in Patients With Chronic Low Back Pain
The purpose of the study was to characterize the safety, effectiveness, and impact on quality of life (QOL) measures of OROS® hydromorphone HCL in patients with chronic low back pain.
- Trial name
- NCT00398788
- Testing
- OROS® hydromorphone HCL; Dilaudid CR (controlled release); Dilaudid IR (immediate release) as rescue medicine
- Volunteers
- 207 people
- Sponsor
- Alza Corporation, DE, USA
Chronic Low-back Pain, Degenerative Disc Disease
Safety, Tolerability, and Effectiveness of Intramuscular Injection of CELZ-201-DDT for the Treatment of Chronic Lower Back Pain
The brief purpose of this research study is to learn about the safety, tolerability, and efficacy of paraspinal intramuscular injection of CELZ-201-DDT in patients with chronic lower back pain.
- Trial name
- ADAPT (NCT06053242)
- Testing
- CELZ-201-DDT
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Creative Medical Technology Holdings Inc
Intubating Conditions, Fasciculations
Muscle Relaxation for Short Procedures
Succinylcholine is commonly used for neuromuscular relaxation for short procedures such as rigid bronchoscopy. A more modern alternative is the application of low-dose rocuronium, reversed by low-dose sugammadex.
- Conditions
- Intubating Conditions, Fasciculations, Postoperative Myalgia, Patient Satisfaction
- Trial name
- NCT01902641
- Testing
- Succinylcholine, Rocuronium/Sugammadex, Rocuronium
- Where
- Germany
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Dr. Horst Schmidt Klinik GmbH
Neonatal Staphylococcal Sepsis
Safety and Pharmacokinetics Study in VLBW Neonates With BSYX-A110
"Phase I/II, Randomized, Double Blind, Placebo Controlled, Dose Escalating, Safety and Pharmacokinetics Study in Very Low Birth Weight Neonates of Four Doses of BSYX-A110 for the Prevention of S.
- Trial name
- N002 (NCT00631878)
- Testing
- Pagibaximab (formerly BSYX-A110)
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Biosynexus Incorporated